[go: up one dir, main page]

Dresel et al., 1987 - Google Patents

Binding of acetylated low density lipoprotein and maleylated bovine serum albumin to the rat liver: one or two receptors?

Dresel et al., 1987

View PDF
Document ID
6076102952490477995
Author
Dresel H
Friedrich E
Via D
Sinn H
Ziegler R
Schettler G
Publication year
Publication venue
The EMBO Journal

External Links

Snippet

The liver is the major organ involved in clearance of acetylated low density lipoprotein (acetyl‐LDL) and maleylated serum albumin (Mal‐BSA). Quantitative analysis of the hepatic uptake by sequential scintigraphy in rats shows that the hepatic uptake capacity for Mal‐BSA …
Continue reading at www.embopress.org (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Similar Documents

Publication Publication Date Title
Dresel et al. Binding of acetylated low density lipoprotein and maleylated bovine serum albumin to the rat liver: one or two receptors?
Pengo et al. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-glycoprotein I is bound to a suitable surface
Almon et al. Interaction of myasthenic serum globulin with the acetylcholine receptor
Shi et al. Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants
Hiemstra et al. Activation of the alternative pathway of complement by human serum IgA
Schultheiss et al. Immunological analysis of auto-antibodies against the adenine nucleotide translocator in dilated cardiomyopathy
US5470570A (en) Mammalian primate erythrocyte bound heteropolymerized monoclonal antibodies and methods of use thereof
Galeano et al. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity
Rothlein et al. A form of circulating ICAM-1 in human serum.
Schlossman et al. Specific fractionation of a population of antidextran molecules with combining sites of various sizes
Pape et al. Characterization of Cytolytic Effector Cells in Peripheral Blood of Healthy Individuals and Cancer Patients: I. Surface Markers and K Cell Activity After Separation of B Cells and Lymphocytes with Fc-Receptors by Column Fractionation
Conrad et al. The interaction of human and rodent IgE with the human basophil IgE receptor.
Conrad et al. Characterization of the Target Cell Receptor for IgE: III. Properties of the Receptor Isolated from Rat Basophilic Leukemia Cells by Affinity Chromatography
JPH06507245A (en) Assay for inhibitors of leukocyte adhesion
Roof et al. Phospholipids enhance the binding of peptides to class II major histocompatibility molecules.
Tertov et al. Naturally occurring modified low density lipoproteins are similar if not identical: more electronegative and desialylated lipoprotein subfractions
Pellegrino et al. Evaluation of two sources of soluble HL‐A antigens: platelets and serum
Nakayama et al. Opsonic properties of C-reactive protein in vivo.
Lang et al. Antigen in tissues: IV. The effect of antibody on the retention and localization of antigen in rat lymph nodes
Lee et al. The murine lymphocyte receptor for IgE. III. Use of chemical cross-linking reagents to further characterize the B lymphocyte Fc epsilon receptor.
Kawana et al. Membrane attack complex of complement in Henoch-Schönlein purpura skin and nephritis
Micklem et al. Analysis of C3-receptor activity on human B-lymphocytes and isolation of the complement receptor type 2 (CR2)
Cormane et al. Immunologic implications of PUVA therapy in psoriasis vulgaris
Sjöberg Presence of receptors for IgD on human T and non‐T lymphocytes
Madaio et al. Effect of antibody charge and concentration on deposition of antibody to glomerular basement membrane